Probability of flare after attaining inactive disease (95% CI) | |||||||
---|---|---|---|---|---|---|---|
N* | Within 6 months | Within 12 months | Within 24 months | ||||
Any flare | Significant flare | Any flare | Significant flare | Any flare | Significant flare | ||
Whole cohort | 1146 | 0.254 (0.229 to 0.282) | 0.154 (0.133 to 0.178) | 0.425 (0.394 to 0.456) | 0.266 (0.240 to 0.295) | 0.603 (0.570 to 0.636) | 0.400 (0.368 to 0.434) |
Systemic arthritis | 68 | 0.268 (0.176 to 0.396) | 0.127 (0.065 to 0.238) | 0.387 (0.278 to 0.520) | 0.179 (0.103 to 0.300) | 0.486 (0.366 to 0.621) | 0.222 (0.135 to 0.354) |
Oligoarthritis persistent | 457 | 0.226 (0.189 to 0.269 | 0.143 (0.113 to 180) | 0.402 (0.356 to 0.451) | 0.279 (0.238 to 0.325) | 0.594 (0.542 to 0.646) | 0.412 (0.362 to 0.466) |
Oligoarthritis extended | 31 | 0.337 (0.192 to 0.549) | 0.226 (0.108 to 0.435) | 0.415 (0.255 to 0.624) | 0.269 (0.138 to 0.484) | 0.537 (0.343 to 0.757) | 0.467 (0.268 to 0.717) |
RF-negative polyarthritis | 212 | 0.251 (0.196 to 0.319) | 0.163 (0.117 to 0.224) | 0.445 (0.376 to 0.521) | 0.263 (0.205 to 0.334) | 0.618 (0.542 to 0.694) | 0.390 (0.318 to 0.471) |
RF-positive polyarthritis | 35 | 0.389 (0.242 to 0.583) | 0.192 (0.091 to 0.379) | 0.598 (0.429 to 0.772) | 0.329 (0.192 to 0.526) | 0.770 (0.595 to 0.908) | 0.515 (0.338 to 0.719) |
Psoriatic arthritis | 75 | 0.266 (0.174 to 0.393) | 0.171 (0.098 to 0.287) | 0.432 (0.319 to 0.564) | 0.253 (0.163 to 0.380) | 0.609 (0.483 to 0.738) | 0.408 (0.292 to 0.549) |
ERA | 155 | 0.259 (0.192 to 0.345) | 0.126 (0.079 to 0.197) | 0.429 (0.347 to 0.522) | 0.237 (0.171 to 0.323) | 0.628 (0.532 to 0.725) | 0.394 (0.306 to 0.497) |
Undifferentiated arthritis | 113 | 0.290 (0.213 to 0.388) | 0.194 (0.129 to 0.284) | 0.444 (0.353 to 0.547) | 0.297 (0.218 to 0.397) | 0.617 (0.515 to 0.720) | 0.429 (0.333 to 0.540) |
*Number of subjects who attained inactive disease.
ERA, enthesitis-related arthritis; JIA, juvenile idiopathic arthritis; RF, rheumatoid factor.